BETHESDA, Md., Feb. 14, 2024 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc., (Nasdaq:GANX), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced it is holding a 2024 Research & Development update on recent in vivo data for GT-02287 along with valuable insights from Key Opinion Leaders.
NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.
